Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Livestock Vaccine Market

ID: MRFR/HC/40346-HCR
200 Pages
Satyendra Maurya
Last Updated: May 18, 2026

Livestock Vaccine Market Research Report By Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, DNA Vaccines), By Livestock Type (Cattle, Poultry, Swine, Sheep, Goats), By Administration Route (Intramuscular, Subcutaneous, Oral, Intranasal), By Disease Type (Bacterial Diseases, Viral Diseases, Parasitic Diseases) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Livestock Vaccine Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Vaccine Type (USD Billion) | |
      1. 4.1.1 Inactivated Vaccines | |
      2. 4.1.2 Live Attenuated Vaccines | |
      3. 4.1.3 Subunit Vaccines | |
      4. 4.1.4 DNA Vaccines |
    2. 4.2 Healthcare, BY Livestock Type (USD Billion) | |
      1. 4.2.1 Cattle | |
      2. 4.2.2 Poultry | |
      3. 4.2.3 Swine | |
      4. 4.2.4 Sheep | |
      5. 4.2.5 Goats |
    3. 4.3 Healthcare, BY Administration Route (USD Billion) | |
      1. 4.3.1 Intramuscular | |
      2. 4.3.2 Subcutaneous | |
      3. 4.3.3 Oral | |
      4. 4.3.4 Intranasal |
    4. 4.4 Healthcare, BY Disease Type (USD Billion) | |
      1. 4.4.1 Bacterial Diseases | |
      2. 4.4.2 Viral Diseases | |
      3. 4.4.3 Parasitic Diseases |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Zoetis (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Merck Animal Health (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Boehringer Ingelheim (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Elanco Animal Health (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Ceva Santé Animale (FR) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Virbac (FR) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Heska Corporation (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Vetoquinol (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY VACCINE TYPE |
    7. 6.4 US MARKET ANALYSIS BY LIVESTOCK TYPE |
    8. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    9. 6.6 US MARKET ANALYSIS BY DISEASE TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY VACCINE TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY LIVESTOCK TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    13. 6.10 CANADA MARKET ANALYSIS BY DISEASE TYPE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY VACCINE TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY LIVESTOCK TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    18. 6.15 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
    19. 6.16 UK MARKET ANALYSIS BY VACCINE TYPE |
    20. 6.17 UK MARKET ANALYSIS BY LIVESTOCK TYPE |
    21. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    22. 6.19 UK MARKET ANALYSIS BY DISEASE TYPE |
    23. 6.20 FRANCE MARKET ANALYSIS BY VACCINE TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY LIVESTOCK TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    26. 6.23 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY VACCINE TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY LIVESTOCK TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
    31. 6.28 ITALY MARKET ANALYSIS BY VACCINE TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY LIVESTOCK TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    34. 6.31 ITALY MARKET ANALYSIS BY DISEASE TYPE |
    35. 6.32 SPAIN MARKET ANALYSIS BY VACCINE TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY LIVESTOCK TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    38. 6.35 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY VACCINE TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY LIVESTOCK TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY VACCINE TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY LIVESTOCK TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    47. 6.44 CHINA MARKET ANALYSIS BY DISEASE TYPE |
    48. 6.45 INDIA MARKET ANALYSIS BY VACCINE TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY LIVESTOCK TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    51. 6.48 INDIA MARKET ANALYSIS BY DISEASE TYPE |
    52. 6.49 JAPAN MARKET ANALYSIS BY VACCINE TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY LIVESTOCK TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    55. 6.52 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY VACCINE TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY LIVESTOCK TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY VACCINE TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY LIVESTOCK TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
    64. 6.61 THAILAND MARKET ANALYSIS BY VACCINE TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY LIVESTOCK TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    67. 6.64 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY VACCINE TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY LIVESTOCK TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY VACCINE TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY LIVESTOCK TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY VACCINE TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY LIVESTOCK TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
    81. 6.78 MEXICO MARKET ANALYSIS BY VACCINE TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY LIVESTOCK TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    84. 6.81 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY VACCINE TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY LIVESTOCK TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY LIVESTOCK TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY VACCINE TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY LIVESTOCK TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY VACCINE TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY LIVESTOCK TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY VACCINE TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY LIVESTOCK TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY LIVESTOCK TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY LIVESTOCK TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY LIVESTOCK TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY DISEASE TYPE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Vaccine Type (USD Billion, 2025-2035)

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Subunit Vaccines
  • DNA Vaccines

Healthcare By Livestock Type (USD Billion, 2025-2035)

  • Cattle
  • Poultry
  • Swine
  • Sheep
  • Goats

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intranasal

Healthcare By Disease Type (USD Billion, 2025-2035)

  • Bacterial Diseases
  • Viral Diseases
  • Parasitic Diseases

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions